Free Trial
→ Your book attached (From Profits Run) (Ad)tc pixel Free MDNA Stock Alerts

Medicenna Therapeutics (MDNA) Competitors

Medicenna Therapeutics logo
C$0.62 0.00 (0.00%)
As of 03:59 PM Eastern
Compare

MDNA vs. IPA, APM, GXE, CGC, and WMD

Should you be buying Medicenna Therapeutics stock or one of its competitors? The main competitors of Medicenna Therapeutics include ImmunoPrecise Antibodies (IPA), Andean Precious Metals (APM), Gear Energy (GXE), Canadian Gold (CGC), and WeedMD (WMD). These companies are all part of the "pharmaceutical products" industry.

How does Medicenna Therapeutics compare to ImmunoPrecise Antibodies?

ImmunoPrecise Antibodies (CVE:IPA) and Medicenna Therapeutics (TSE:MDNA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.

0.4% of Medicenna Therapeutics shares are owned by institutional investors. 22.6% of Medicenna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

ImmunoPrecise Antibodies has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. ImmunoPrecise Antibodies' return on equity of 0.00% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
ImmunoPrecise AntibodiesN/A N/A N/A
Medicenna Therapeutics -533,640.00%-103.51%-32.80%

In the previous week, Medicenna Therapeutics had 1 more articles in the media than ImmunoPrecise Antibodies. MarketBeat recorded 1 mentions for Medicenna Therapeutics and 0 mentions for ImmunoPrecise Antibodies. ImmunoPrecise Antibodies' average media sentiment score of 0.00 equaled Medicenna Therapeutics'average media sentiment score.

Company Overall Sentiment
ImmunoPrecise Antibodies Neutral
Medicenna Therapeutics Neutral

ImmunoPrecise Antibodies has higher revenue and earnings than Medicenna Therapeutics. ImmunoPrecise Antibodies is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunoPrecise AntibodiesC$19.47M8.33-C$22.19M-C$0.89N/A
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.15N/A

Summary

ImmunoPrecise Antibodies and Medicenna Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Medicenna Therapeutics compare to Andean Precious Metals?

Medicenna Therapeutics (TSE:MDNA) and Andean Precious Metals (CVE:APM) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

0.4% of Medicenna Therapeutics shares are owned by institutional investors. Comparatively, 13.2% of Andean Precious Metals shares are owned by institutional investors. 22.6% of Medicenna Therapeutics shares are owned by company insiders. Comparatively, 69.4% of Andean Precious Metals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Andean Precious Metals has a net margin of 16.17% compared to Medicenna Therapeutics' net margin of -533,640.00%. Andean Precious Metals' return on equity of 20.32% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Medicenna Therapeutics-533,640.00% -103.51% -32.80%
Andean Precious Metals 16.17%20.32%4.13%

In the previous week, Medicenna Therapeutics had 1 more articles in the media than Andean Precious Metals. MarketBeat recorded 1 mentions for Medicenna Therapeutics and 0 mentions for Andean Precious Metals. Medicenna Therapeutics' average media sentiment score of 0.00 equaled Andean Precious Metals'average media sentiment score.

Company Overall Sentiment
Medicenna Therapeutics Neutral
Andean Precious Metals Neutral

Andean Precious Metals has higher revenue and earnings than Medicenna Therapeutics. Medicenna Therapeutics is trading at a lower price-to-earnings ratio than Andean Precious Metals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.15N/A
Andean Precious MetalsC$154.78M0.88C$37.41MC$0.512.55

Medicenna Therapeutics has a beta of 2.84393, meaning that its stock price is 184% more volatile than the S&P 500. Comparatively, Andean Precious Metals has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500.

Summary

Andean Precious Metals beats Medicenna Therapeutics on 9 of the 11 factors compared between the two stocks.

How does Medicenna Therapeutics compare to Gear Energy?

Medicenna Therapeutics (TSE:MDNA) and Gear Energy (TSE:GXE) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

0.4% of Medicenna Therapeutics shares are owned by institutional investors. Comparatively, 2.4% of Gear Energy shares are owned by institutional investors. 22.6% of Medicenna Therapeutics shares are owned by company insiders. Comparatively, 7.6% of Gear Energy shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Medicenna Therapeutics has a beta of 2.84393, meaning that its stock price is 184% more volatile than the S&P 500. Comparatively, Gear Energy has a beta of 3.52, meaning that its stock price is 252% more volatile than the S&P 500.

In the previous week, Medicenna Therapeutics had 1 more articles in the media than Gear Energy. MarketBeat recorded 1 mentions for Medicenna Therapeutics and 0 mentions for Gear Energy. Medicenna Therapeutics' average media sentiment score of 0.00 equaled Gear Energy'saverage media sentiment score.

Company Overall Sentiment
Medicenna Therapeutics Neutral
Gear Energy Neutral

Gear Energy has a net margin of 5.77% compared to Medicenna Therapeutics' net margin of -533,640.00%. Gear Energy's return on equity of 3.52% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Medicenna Therapeutics-533,640.00% -103.51% -32.80%
Gear Energy 5.77%3.52%4.84%

Gear Energy has higher revenue and earnings than Medicenna Therapeutics. Medicenna Therapeutics is trading at a lower price-to-earnings ratio than Gear Energy, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.15N/A
Gear EnergyC$134.93M0.00C$13.02MC$0.05N/A

Summary

Gear Energy beats Medicenna Therapeutics on 9 of the 11 factors compared between the two stocks.

How does Medicenna Therapeutics compare to Canadian Gold?

Medicenna Therapeutics (TSE:MDNA) and Canadian Gold (CVE:CGC) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

0.4% of Medicenna Therapeutics shares are owned by institutional investors. Comparatively, 0.3% of Canadian Gold shares are owned by institutional investors. 22.6% of Medicenna Therapeutics shares are owned by company insiders. Comparatively, 43.3% of Canadian Gold shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Medicenna Therapeutics has a beta of 2.84393, suggesting that its stock price is 184% more volatile than the S&P 500. Comparatively, Canadian Gold has a beta of -1.586234, suggesting that its stock price is 259% less volatile than the S&P 500.

In the previous week, Medicenna Therapeutics had 1 more articles in the media than Canadian Gold. MarketBeat recorded 1 mentions for Medicenna Therapeutics and 0 mentions for Canadian Gold. Medicenna Therapeutics' average media sentiment score of 0.00 equaled Canadian Gold'saverage media sentiment score.

Company Overall Sentiment
Medicenna Therapeutics Neutral
Canadian Gold Neutral

Canadian Gold has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. Canadian Gold's return on equity of -92.98% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Medicenna Therapeutics-533,640.00% -103.51% -32.80%
Canadian Gold N/A -92.98%-48.06%

Canadian Gold is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.15N/A
Canadian GoldN/AN/A-C$3.62M-C$0.02N/A

Summary

Medicenna Therapeutics and Canadian Gold tied by winning 5 of the 10 factors compared between the two stocks.

How does Medicenna Therapeutics compare to WeedMD?

Medicenna Therapeutics (TSE:MDNA) and WeedMD (CVE:WMD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

In the previous week, Medicenna Therapeutics had 1 more articles in the media than WeedMD. MarketBeat recorded 1 mentions for Medicenna Therapeutics and 0 mentions for WeedMD. Medicenna Therapeutics' average media sentiment score of 0.00 equaled WeedMD'saverage media sentiment score.

Company Overall Sentiment
Medicenna Therapeutics Neutral
WeedMD Neutral

Medicenna Therapeutics has higher earnings, but lower revenue than WeedMD. Medicenna Therapeutics is trading at a lower price-to-earnings ratio than WeedMD, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medicenna TherapeuticsN/AN/A-C$25.98M-C$0.15N/A
WeedMDC$27.53M2.46-C$102.60M-C$0.42N/A

WeedMD has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. WeedMD's return on equity of 0.00% beat Medicenna Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Medicenna Therapeutics-533,640.00% -103.51% -32.80%
WeedMD N/A N/A N/A

0.4% of Medicenna Therapeutics shares are owned by institutional investors. 22.6% of Medicenna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Medicenna Therapeutics and WeedMD tied by winning 5 of the 10 factors compared between the two stocks.

Get Medicenna Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MDNA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MDNA vs. The Competition

Export
MetricMedicenna TherapeuticsBiotechnology IndustryMedical SectorTSE Exchange
Market CapC$51.72MC$446.06MC$6.25BC$11.72B
Dividend YieldN/A3.86%2.73%6.22%
P/E Ratio-4.134.1929.0423.83
Price / SalesN/A6,879.71476.6113.46
Price / Cash1.1513.1327.6282.69
Price / Book8.3377.749.674.48
Net Income-C$25.98M-C$96.07MC$3.55BC$300.68M
7 Day Performance8.77%0.71%1.70%0.12%
1 Month PerformanceN/A3.87%5.62%2.88%
1 Year Performance-40.38%48.54%34.42%57.78%

Medicenna Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MDNA
Medicenna Therapeutics
N/AC$0.62
flat		N/AN/AC$51.72MN/AN/A20
IPA
ImmunoPrecise Antibodies
N/AC$6.50
+0.8%		N/AN/AC$162.08MC$19.47MN/A80
APM
Andean Precious Metals
N/AC$1.29
+7.5%		N/AN/AC$135.47MC$154.78M2.5530
GXE
Gear Energy
N/AN/AN/AN/AC$126.52MC$134.93M10.391,310
CGC
Canadian Gold
N/AC$0.60
-6.3%		N/AN/AC$126.35MN/AN/A3,150

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:MDNA) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel